181,89 €
inkl. MwSt.
Sofort per Download lieferbar
  • Format: PDF

This book addresses the therapeutic strategies to target mitochondrial metabolism in diseases where the function of that organelle is compromised, and it discusses the effective strategies used to create mitochondrial-targeted agents that can become commercially available drug delivery platforms. The consistent growth of research focused in understanding the multifaceted role of mitochondria in cellular metabolism, controlling pathways related with cell death, and ionic/redox regulation has extended the research of mitochondrial chemical-biological interactions to include various…mehr

Produktbeschreibung
This book addresses the therapeutic strategies to target mitochondrial metabolism in diseases where the function of that organelle is compromised, and it discusses the effective strategies used to create mitochondrial-targeted agents that can become commercially available drug delivery platforms. The consistent growth of research focused in understanding the multifaceted role of mitochondria in cellular metabolism, controlling pathways related with cell death, and ionic/redox regulation has extended the research of mitochondrial chemical-biological interactions to include various pharmacological and toxicological applications. Not only does the book extensively cover basic mitochondrial physiology, but it also links the molecular interactions within these pathways to a variety of diseases. It is one of the first books to combine state-of-the-art reviews regarding basic mitochondrial biology, the role of mitochondrial alterations in different diseases, and the importance of that organelle as a target for pharmacological and non-pharmacological interventions to improve human health. The different chapters highlight the chemical-biological linkages of the mitochondria in context with drug development and clinical applications.

Autorenporträt
Paulo J. Oliveira is recognized for his work as the Coordinator of the Mitochondrial, Metabolism, and Disease Group at the Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Portugal and is the current Vice-President of the European Society of Clinical Investigation (ESCI). He has previously spent some time at the University of Minnesota Medical School, Duluth, investigating the mitochondrial mechanisms of anthracycline-induced selective cardiotoxicity. Throughout his career, he has been involved in projects in which the objective was to advance fundamental knowledge and methodological aspects of mitochondrial research. His current research interests include the role of mitochondria in cardiovascular and liver diseases, the relationship between mitochondrial remodeling and (cancer) stem cell biology, development of novel mitochondrial-targeted therapeutics, as well as the mechanisms of drug-related mitochondrial toxicity. Dr. Oliveira has co-authored close to 200 publications focusing on mitochondrial research.